COVID‐19: Outpatient Management in Adults
MP Dubé - Coronavirus Disease 2019 (COVID‐19) A Clinical …, 2023 - Wiley Online Library
Worldwide, most COVID‐19 cases are managed outside of the hospital setting. For
individuals with mild to moderate disease with a lower risk for illness progression and life …
individuals with mild to moderate disease with a lower risk for illness progression and life …
[PDF][PDF] Neutralising antibody responses against HIV-1 and SARS-CoV-2.
C Graham - 2023 - kclpure.kcl.ac.uk
Understanding how viruses and antibodies evolve in response to one another can help
inform future vaccines and therapies. This project investigated longitudinal samples from …
inform future vaccines and therapies. This project investigated longitudinal samples from …
In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG. 5 and BA. 2.86
D Ashoor, MD Fathallah - 2023 - preprints.org
The current globally dominant SARS-CoV-2 variants are showing immune escape and
reduced susceptibility to antiviral drugs. Therefore, agencies responsible for drug evaluation …
reduced susceptibility to antiviral drugs. Therefore, agencies responsible for drug evaluation …
[PDF][PDF] Deep Structural Analysis of Myriads of Omicron Sub-variants Revealed Hotspot for Vaccine Escape Immunity. Vaccines 2023, 11, 668
V Gerardi, MA Rohaim, RFE Naggar, MO Atasoy… - 2023 - researchgate.net
The emergence of the Omicron variant has reinforced the importance of continued SARS-
CoV-2 evolution and its possible impact on vaccine effectiveness. Specifically, mutations in …
CoV-2 evolution and its possible impact on vaccine effectiveness. Specifically, mutations in …
Predicting the past and future evolutionary space of SARS-CoV-2
SARS-CoV-2 emerged in the human population in late 2019 1, 2, went through population
bottlenecks 3 and has undergone adaptation and evolution by single nucleotide …
bottlenecks 3 and has undergone adaptation and evolution by single nucleotide …
Mutational insights among the structural proteins of SARS-CoV-2; comprehensive analyses in the six continents
M Abavisani, K Rahimian, B Mahdavi, S Tokhanbigli… - 2022 - researchsquare.com
Background: Mutations among the structural proteins of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) can lead to the emergence of new variants with different …
coronavirus 2 (SARS-CoV-2) can lead to the emergence of new variants with different …
Molecular Recognition of Ligands in G Protein-Coupled Receptors, Guanine in GTP-Binding Proteins, and SARS-CoV-2 Spike Proteins by ACE2
P Bhatta - 2022 - search.proquest.com
Molecular recognition between two or more molecular binding partners plays an essential
role in many cellular processes and pathogen entry steps. It is widely accepted now that …
role in many cellular processes and pathogen entry steps. It is widely accepted now that …
Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+ etesevimab, sotrovimab) in patients with COVID-19
VM Tsvetov, IS Burashnikova, DA Sychev - Pharmateca, 2021 - bioethicsjournal.ru
Currently, there are prerequisites, such as data from phase 2 and 3 multicenter clinical trials,
to recommend sotrovimab and bamlanivimab+ etesevimab at the prehospital stage for …
to recommend sotrovimab and bamlanivimab+ etesevimab at the prehospital stage for …
大阪府におけるsevere acute respiratory syndrome coronavirus 2 の系統解析およびスパイクタンパク質の変異解析
若林友騎， 河原隆二， 柿本健作， 山口貴弘… - … 健康安全基盤研究所編, 2023 - jstage.jst.go.jp
2022 年 1 月 1 日から 2022 年 12 月 31 日までに大阪府内で検出され, 全ゲノム配列が解読され
た severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) について …
た severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) について …